Status:
RECRUITING
Immunogenicity of 9-valent HPV Vaccine
Lead Sponsor:
Talia Sainz Costa
Conditions:
Human Papilloma Virus Infection
Eligibility:
All Genders
9-18 years
Phase:
PHASE4
Brief Summary
Human papillomavirus (HPV) causes the most prevalent sexually transmitted infections in the world. The nonavalent HPV vaccine (9vHPV) provides protection against 9 high-risk HPV serotypes, responsible...
Eligibility Criteria
Inclusion
- Children or adolescents 9 to \<18 years of age
- Willing to sign consent/assent form
- If HIV positive, under ART and undetectable viral load and CD4 cell count \>200/mm3 (at least 6 months)
- If the patient has received chemotherapy or is a SOT/HSCT recipient, referred for immunizations after adequate immune reconstitution according to routine clinical practice
Exclusion
- Previous history of warts and/or anal cancer.
- Previous immunization with any HPV vaccine.
- Age below 9.
- Patients who for any reason should not be included in the study according to the evaluation of the research team.
Key Trial Info
Start Date :
March 7 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2025
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT05439083
Start Date
March 7 2023
End Date
March 1 2025
Last Update
March 8 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Universitario La paz
Madrid, Spain, 28046